Potentiating Psilocybin

增强裸盖菇素

• 批准号: 10354547
• 负责人: DAVID E CLIFFEL
• 金额: $ 23.78万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-05 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10354547
• 关键词: Acer; Alder plant; Beta Carbolines; Biochemical; Cessation of life; Chemicals; Chemistry; Chronic; Cities; Clinical Treatment; Development; Disease; Disease model; Dose; Drug Interactions; Fruit; Grain; Grant; Growth; Hallucinogens; Harvest; Heterogeneity; Human; Humidity; Ingestion; Learning; Legal; Link; Liquid substance; Major Depressive Disorder; Maps; Mental Depression; Mental disorders; Migraine; Modeling; Modern Medicine; Monitor; Monoamine Oxidase Inhibitors; Names; Neurons; Paper; Patients; Pharmaceutical Preparations; Physiological; Plants; Psychotherapy; Publishing; Recording of previous events; Reporting; Research; Research Personnel; Resources; Rye cereal; Sampling; Selective Serotonin Reuptake Inhibitor; Serotonergic System; Serotonin; Serotonin Syndrome; Signal Transduction; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stable Isotope Labeling; Structure; Supplementation; Techniques; Technology; Temperature; Testing; Therapeutic Effect; Toxicology; Tryptophan; Variant; Wheat; base; common treatment; comparative; detection method; high risk; inhibitor therapy; instrument; interest; painful neuropathy; plant fungi; psilocin; psychologic; screening; small molecule; treatment-resistant depression; uptake

PROJECT SUMMARY ABSTRACT Plants and fungi have a long history of medicinal use yet, modern medicine has turned away from plant-based medicinals due to heterogeneity that results in inconsistent and unpredictable dosing. In 2018, psilocybin was granted Breakthrough Therapy Designation for the therapy of treatment-resistant depression. Initial results of psychedelic-assisted psychotherapy using the psilocybin molecule to treat major depressive disorder report sustained relief from chronic conditions after just one treatment—a breakthrough treatment indeed. In our understanding, these studies—and many others investigating psilocybin’s effect on a range of conditions—rely on the psilocybin molecule as the active compound, not Psilocybin Sp.. As this treatment gains support, it’s important to consider the differences between the molecule psilocybin and various Psilocybin species. In 2019 Blei et. al. published an unexpected paper revealing that β- carbolines—monoamine oxidase inhibitors (MAOIs)—are also found in five common Psilocybin sp.. Generally, MAOIs are considered to be counter indicated with Selective Serotonin Reuptake Inhibitors (SSRIs)—common treatments for psychiatric disorders, migraine headaches and neuropathic pain. In fact, patients taking SSRIs have developed serotonin syndrome after ingesting mixtures of serotonergic psychedelics and MAOIs—overwhelming the serotonin system and resulting in death. These counter indications are absent in research that relies exclusively on the psilocybin molecule. It is therefore of critical importance that we understand the chemistry of various psilocybin- containing mushrooms so that clinicians, researchers, policymakers, and the public can make informed decisions. To this end, we propose investigating the β-carboline content in 13 different psilocybin-containing species. (Aim 1), the growth conditions that may vary this content (Aim 2), and their effects on the serotonin system (Aim 3). As city and state legislatures are now legalizing and/or decriminalizing Psilocybin sp., these potential drug interactions represent a high-risk to current SSRI patients. With over 100 different species of psilocybin-containing mushrooms spanning at least six genera, there is a lot to learn as legalization proceeds.

项目摘要摘要 植物和真菌的医疗用途历史悠久，现代医学已经脱离了 由于异质性而导致的植物性药物，导致不一致和不可预测 给药。 2018年，psylocybin被授予突破性疗法名称用于治疗 耐治疗抑郁症。使用迷幻辅助心理治疗的初步结果 psilocybin分子以治疗重度抑郁症报告持续缓解慢性 只有一种治疗后的条件 - 确实是突破性疗法。在我们的理解中 这些研究以及许多其他研究psilocybin对各种条件的影响的研究很少 在psilocybin分子作为活性化合物上，而不是psilocybin sp。 支持，重要的是要考虑分子psilocybin和各种差异 psilocybin物种。在2019年Blei等。 al。发表了一篇意想不到的论文，揭示了β- 在五个常见的psilocybin中也发现了碳水化合物 - 氧化物抑制剂（MAOI） Sp ..通常，MAOI被认为与选择性5-羟色胺再摄取相反 抑制剂（SSRI） - 精神疾病，偏头痛标头的常见治疗方法 神经性疼痛。实际上，服用SSRI的患者在 血清素能迷幻和毛伊斯的摄入混合物 - 使5-羟色胺系统的混合物摄取 并导致死亡。在研究中没有这些反迹象，这完全依赖于 psylocybin分子。因此，我们了解化学是至关重要的 含有肌肉的各种psilocybin，以使临床医生，研究人员，决策者和 公众可以做出明智的决定。为此，我们建议研究β-碳酸盐 含有13种不同的含psilocybin物种的物种。 （AIM 1），增长条件可能 改变此内容（AIM 2）及其对5-羟色胺系统的影响（AIM 3）。作为城市和州 立法机关现在正在使这些潜在药物合法化和/或非刑事化psilocybin sp。 相互作用代表当前SSRI患者的高风险。超过100种不同的物种 至少六属含有psilocybin的肌肉，有很多东西要学 合法化收益。